胸腺瘤表皮生长因子受体、增殖细胞核抗原、Bcl-2和Bax表达及临床意义

目的　探讨胸腺瘤表皮生长因子受体 ( EGFR)、增殖细胞核抗原 ( PCNA)、Bcl- 2和 Bax的表达与胸腺瘤临床病理特征的关系及临床意义。　方法　应用免疫组织化学链霉素亲生物蛋白 -过氧化酶 ( S- P)法检测 4 6例胸腺瘤患者EGFR、PCNA、Bcl- 2和 Bax的表达。　结果　胸腺瘤 EGFR阳性表达率为 71.7% ,PCNA标记指数为 4 .0 0 %± 1.87% ,Bcl- 2、Bax阳性率分别为 4 1.3 %、15 .2 %。EGFR表达与胸腺瘤 Masaoka分期、肿瘤性质有明显关系 ,EGFR阴性者术后生存率显著高于阳性者 ( P=0 .0 0 5 )。 PCNA标记指数和 Bcl- 2与胸腺瘤肿瘤性质有明显关系 ,Bcl- 2阴性者术后生存率显著高于阳性者 ( P=0 .0 0 2 )。EGFR、PCNA、Bcl- 2和 Bax表达均与胸腺瘤组织学类型、是否合并重症肌无力无明显关系。　结论　EGFR与胸腺瘤的发生、发展有关 ,可作为 Masaoka分期的补充推测预后。Bcl- 2与胸腺癌发生有关 ,可作为胸腺癌的标记物用于鉴别诊断。     

胃不典型增生和癌组织中Ki67和PTEN蛋白的表达及意义

目的研究胃正常组织、不典型增生组织和癌组织中Ki67和PTEN蛋白的表达情况，探讨其与胃组织癌变的关系及作为早期癌变生物学标志的可能性。方法应用免疫组织化学SP法对22例胃正常组织、80例不典型增生组织及60例胃癌组织中Ki67和PTEN蛋白的表达情况进行检测。结果在胃正常组织、不典型增生组织及胃癌组织中PTEN蛋白的表达阳性率呈递减趋势，Ki67蛋白则呈递增趋势；等级相关分析结果显示PTEN和Ki67表达阳性率与胃黏膜组织从正常至不典型增生再至癌变这一过程均相关（r分别为-0．461和0．301，P〈0．01）。PTEN的表达与胃癌的Lauren分型、分化程度、浸润深度无关，与淋巴结转移有关。Ki67的表达与胃癌的Lauren分型、淋巴结转移有关，与浸润深度、分化程度无关。PTEN和Ki67蛋白的表达在胃癌组织中呈负相关（r=-0．316，P〈0．05）。结论Ki67和PTEN蛋白的表达异常与胃癌的癌变过程相关，两者有可能成为胃组织早期癌变的分子标记物。     

PTEN蛋白和p27在胃癌中的表达和相关性研究

目的：研究胃癌中抑癌基因PTEN和p27的表达和丽者间的关系.方法：应用免疫组化方法检测36例胃癌组织、10例癌旁组织和8例正常胃组织中PTEN和p27蛋白的表达情况.结果：胃癌组织中PTEN和p27阳性表达率分别为61.1%（22/36）和63.9%（23/36）（P＞0.05）,均低于正常胃组织阳性率100%（P＜0.05）胃癌组织中PTEN和p27阳性表达存在正相关关系（r=0.3043 P＜0.05）,结论：PTEN和p27基因的异常改变参与胃粘膜细胞的恶性转化过程,PTEN和p27蛋白表达水平可作为评价胃癌病理生物学行为的客观指标之一.     

表皮生长因子受体和血管内皮生长因子在胃肠间质瘤中的表达及其意义

目的 观察表皮生长因子受体(EGFR)和血管内皮生长因子(VEGF)在胃肠间质瘤(GIST)中的表达,分析其临床意义.方法 采用免疫组织化学SP法检测107例GIST中EGFR和VEGF的染色和表达情况,分析其和临床病理因素、预后的关系.结果 EGFR和VEGF在GIST中的阳性表达率分别为91.6%和40.2%.EGFR在直径较大(τ=0.533,P<0.01)、高风险分级(τ=0.663,P<0.01)和预后较差(X2=18.902,P<0.01,Log-rank检验)的GIST患者中染色强度加深;VEGF在<50岁(X2=14.10,P<0.01)、小肠(X2=9.88,P<0.01)、直径较大肿瘤(H=22.556,P<0.01)、高风险分级(H=20.908,P<0.01)和预后差(X2=42.378,P<0.01,Log-rank检验)的GIST患者中表达升高.结论 EGFR的染色强度和VEGF的表达有助于判断GIST患者的恶性程度和预后.     

表皮生长因子受体在胰腺导管内乳头状黏液性肿瘤中的表达及其临床意义

目的研究表皮生长因子受体(epidermal growth factor receptor,EGFR)在胰腺导管内乳头状黏液性肿瘤(intraductal papillary mucinous tumor,IPMT)中的表达,并探讨其临床意义。方法采用免疫组织化学方法观察40例IPMT及20例胰腺导管腺癌(pancreatic ductal adenocarcinoma,DAC)组织中EGFR的表达,并结合临床病理资料作统计学分析。结果在40例IPMT中,17例EGFR表达阳性,占42.5%。其中,19例IPMA中,4例EGFR表达阳性,占21.05%;21例IPMB+IPMC中,13例EGFR表达阳性,占62%。在20例DAC中,有16例EGFR表达呈阳性,占80%。在恶性程度高的DAC中,EGFR的表达量显著高于IPMT(P0.05);IPMB+IPMC中EGFR的表达量亦显著高于IPMA(P0.05)。结论EGFR可能是IPMT恶变的重要标识,其在IPMT的恶性发展中可能起到重要作用。     

表皮生长因子受体相关蛋白在胃癌组织中的表达及临床意义

目的 观察表皮生长因子受体相关蛋白(ERRP)的表达以及细胞增殖在胃癌分化和发展中的作用.方法 观察47例患者胃癌的手术标本中ERRP的表达和定位,并将其与良性胃黏膜比较,确定他们与细胞增殖和分化的关系.检测3种不同的胃癌细胞株中ERRP的表达,并用表皮生长因子(EGF)诱导EGFR磷酸化激活MKN-28胃癌细胞,检测ERRP对此效应的作用.结果 与良性胃黏膜(66％标本阳性)比较,胃癌(33％标本阳性)中ERRP的表达显著降低.正常胃黏膜的ERRP染色评分是2.9(0.3),高分化、中度分化和低分化癌的评分分别是2.6(0.6)、0.9(0.6)和1.0(0.5),ERRP表达的降低与恶性程度的组织学分级呈负相关(P＜0.05).ERRP阴性癌细胞[35.3(1.1)％;P＜0.01]中增殖程度是ERRP附性癌细胞[9.4(0.6)％]的3.5倍,ERRP在癌细胞中的表达与细胞增殖也呈负相关.与源于非转移性癌的细胞AGC比较,源于转移性胃癌细胞MKN-28和NCI-N87中ERRP的表达量分别是其的1.7倍和2倍.外源性的ERRP蛋白明显抑制了EGF诱导的胃癌细胞MKN-28中EGFR的磷酸化,抑制程度为45倍.结论 ERRP的下调可能在胃癌分化和发展中起重要的作用.ERRP对肿瘤细胞增殖具有负调控作用,其抑制作用可能部分是通过减弱EGFR的活化来实现的.     

转化生长因子α及表皮生长因子受体与Ki-67在肾母细胞瘤组织中的表达及意义

目的 探讨转化生长因子-α（TGF-α）、表皮生长因子受体（EGFR）和增殖相关抗原Ki-67在肾母细胞瘤组织中的表达及意义。方法 应用免疫组化方法检测8例正常肾组织、35例肾母细胞瘤组织和14例瘤旁组织中TGF-α、EGFR和Ki-67的表达，比较其在3种组织中及不同病理学特征的肾母细胞瘤组织中的表达差异。结果 肾母细胞瘤组织中TGF-α、EGFR和Ki-67阳性表达率分别为51．4％（18／35）、62．9％（22／35）和68．6％（24／35），显著高于瘤旁组织（14．3％、28．6％、7．1％）和正常肾组织（P〈0.05）。TGF-α、EGFR和Ki-67表达与肾母细胞瘤患儿性别、年龄、病理学分型、肿瘤大小和部位无关（P〉0．05），与临床分期明显相关（P〈0．05）。Speαrman相关分析提示TGF-α、EGFR和Ki-67间呈正相关关系。结论 TGF-α／EGFR自分泌环路在肾母细胞瘤发生发展中起重要作用，并与肿瘤细胞增殖密切相关。     

表皮生长因子和表皮生长因子受体在隐睾症男童表达的改变及其临床意义

目的:探讨表皮生长因子(EGF)及表皮生长因子受体(EGFR)在隐睾症男童的表达改变及其临床意义。方法：用放射性免疫法测定血清EGF，免疫组化法测定EGFR表达。结果(1)5—9岁及10—14岁隐睾症男童血清EGF水平显著低于正常男童(P＜0．01)，(2)腹腔隐睾症患者的血清EGF水平比腹股沟管内及腹股沟管外隐睾症患者显著为低，(3)睾丸固定术后6个月血清EGF水平显著增高(P＜0．05)，(4)2—4岁患者间质细胞中EGFR的表达显著低于5岁以上的患者(P＜0．05)，(5)腹腔隐睾症及腹股沟管内隐睾症患者的EGFR阳性表达显著低于腹股沟外隐睾症患者(P＜0．01)。结论：EGF及EGFR的表达可能和年龄及睾丸位置有关。睾丸固定术可改善隐睾症男童的EGF及EGFR的表达。     

PTEN、FAK在膀胱移行细胞癌中的表达

目的研究PTEN、FAK在膀胱移行细胞癌中的表达及其临床意义。方法采用免疫组织化学（PowerVision两步法）的方法检测42例膀胱移行细胞癌和8例正常膀胱黏膜标本中PTEN、FAK蛋白的表达,分析各个指标和病理参数的关系。结果膀胱癌组织中PTEN、FAK的阳性表达率分别为69．05％、66．7％,与正常黏膜对比均具有显著性差异（P〈0．05）,随肿瘤的分期分级的升高,PTEN的染色强度具有下降趋势,FAK蛋白的阳性表达呈上升趋势,二者呈负相关。结论PTEN、FAK蛋白表达在膀胱癌的发生、发展中起协同作用,二者的协同检测有助于判断预后。     

肝细胞癌患者组织中AFP、PTEN、EGFR表达水平及其临床意义

目的 探讨 AFP、PTEN、EGFR 在肝细胞癌 (HCC)组织中的表达水平及其临床意义 。 方法 选取 2019 年 6 月至 2022 年 6 月38 例 HCC 组织作为观察组,同时期内 34 例正常肝组织为对照组。 免疫组化法检测所有组织中 AFP、PTEN、EGFR 表达水平。 比较两组 AFP、PTEN、EGFR 表达情况;分析 HCC 患者 AFP、PTEN、EGFR 表达与临床病理学参数之间相关性;分析 HCC 患者 AFP 表达与 PTEN、EGFR 表达之间相关性;分析 HCC 患者 AFP、PTEN、EGFR 表达及临床病理学参数对 HCC 预后的影响。 结果 观察组 AFP、PTEN、EGFR 表达阳性率显著高于对照组,存在统计学差异(P<0.05)。 HCC 患者 AFP 阳性表达与 HBsAg、病灶直径、病理分化程度、TNM 分期及术后 2 年内复发情况之间存在联系(P<0.05);PTEN 阳性表达与淋巴结转移、TNM 分期及术后 2 年内复发情况之间存在联系(P<0.05);EGFR 阳性表达与病理分化程度及术后 2 年内复发情况之间...     

表皮生长因子受体,多胺与肺癌的关系

探讨表皮生长因子受体（ＥＧＦＲ）和多胺（ＰＡ）对人肺癌及正常肺组织生长、分化的影响。方法放射性配体结合法检测ＥＧＦＲ含量；高效液相色谱分析法测ＰＡ含量。结果肺癌组织中ＥＧＦＲ的含量（５．６２±４．２６ｆｍｏｌ／ｍｇ膜蛋白）高于非癌肺组织（３．９０５±２．２７９ｆｍｏｌ／ｍｇ膜蛋白），有显著性差异（Ｐ＜０．０１）；肺癌组织ＰＡ的含量亦高于正常肺组织（Ｐ＜０．０１）。结论ＥＧＦＲ和ＰＡ可促使肺癌发展，可作为肺癌的肿瘤标记物     

Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer

Background: Epidermal growth factor receptor (EGFR or HER1) and its homolog c-erbB-2 (HER2) are membrane receptors. Both EGFR and HER2 genes are overexpressed in a variety of solid human cancers and are related to poor prognosis of the patients. The objective of this work was to evaluate the EGFR and HER2 contents in resectable gastric cancer, their possible relationship with clinicopathologic parameters of tumors, and their prognostic significance.Methods: This was a prospective analysis of 63 patients with resectable gastric carcinomas, with a mean follow-up period of 40.7 months. Membranous EGFR levels were examined by radioligand binding assays, and cytosolic HER2 levels were examined by means of an immunoenzymatic assay.Results: There was a wide variability of EGFR (1–1,239 fmol/mg of protein) and HER2 (7–20,863 NHU/mg of protein) levels in tumors. There was no significant correlation between these levels and patient or tumor characteristics. However, high levels of EGFR and HER2 were significantly associated with a shorter overall survival period (P = .03 and P = .02, respectively).Conclusions: There is a wide variability in membranous EGFR levels and in cytosolic HER2 levels in gastric cancer, which seems to be related to the biological heterogeneity of these tumors. In addition, high tumor EGFR and HER2 levels were associated with an unfavorable outcome in patients with resectable gastric cancer.     

Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck

Spindle cell carcinoma (SpCC) is an uncommon head and neck squamous cell carcinoma (SCC) variant consisting of spindled and/or pleomorphic cells with epithelial differentiation. Epidermal growth factor receptor (EGFR) is expressed by >90 % of conventional SCC, and high level expression is associated with a poorer prognosis. Anti-EGFR therapies are commonly used to treat head and neck SCC. However, no studies have evaluated EGFR expression in SpCC. Cases of SpCC were retrieved from department files. The diagnosis required either a biphasic lesion with a squamous neoplastic component, or a purely spindle cell or pleomorphic tumor with immunohistochemical positivity for epithelial markers. EGFR immunohistochemistry was performed and was quantified in quartiles. Medical records were reviewed for clinical follow up information. EGFR was expressed in 21/30 (70 %) cases, including in the squamous component in 18/19 (95 %) and the spindle cell component in only 12/30 (40 %). Where the spindle cell component was positive, the intensity and distribution were lower than for the squamous component. Recurrent tumors were predominantly (80–90 %) of the spindle cell component, and had low (or absent) EGFR expression. Kaplan–Meier survival analysis showed no statistically significant differences in overall or disease free survival between the EGFR expressing and non-expressing groups (p = 0.414 and 0.19, respectively). SpCCs of the head and neck have a poor prognosis, and markedly reduced EGFR expression. EGFR-specific therapies may not be ideal for SpCC patients, which may lack EGFR expression, but further studies are needed.

Electronic supplementary material

The online version of this article (doi:10.1007/s12105-014-0604-y) contains supplementary material, which is available to authorized users.     

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery

Background To investigate the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for prediction of cancer behavior and clinical outcomes in colon cancer patients undergoing potentially curative surgery. Methods EGFR determination using a commercially available immunohistochemistry kit was performed in tissues from 149 colon cancer patients receiving primary surgical treatment and in 25 normal colon mucosa specimens from noncancer patients. EGFR positivity was correlated in univariate and multivariate analyses with disease recurrence and survival. In addition, p27, p53, and vascular endothelial growth factor expression were assessed by immunohistochemistry in 104 patients and correlated with EGFR tumor expression and clinical outcome. Results EGFR expression was detected in approximately one third of colon cancer patients (53 of 149; 35.6%). In 126 curatively treated patients, EGFR expression was correlated with disease recurrence and worse survival in both univariate and multivariate analyses. In a multivariate model for predicting recurrence and survival, Dukes’ staging, p27, and EGFR expression were the only independent covariates. In particular, in Dukes’ A and B patients the 5-year survival probability was 96% for EGFR-negative and high p27 expression cases and was 30.7% for EGFR-positive and low p27 expression cases. Conclusions EGFR expression was an independent prognostic indicator of disease recurrence and poor survival in colon cancer patients undergoing curative surgery. In the context of novel therapeutic options such as molecularly targeted therapies, these findings suggest that anti-EGFR drugs could be evaluated in the adjuvant treatment of EGFR-positive colon cancer patients.     

表皮生长因子受体家族EGFR、c-erbB-2和c-erbB-3在大肠肿瘤中的表达

目的:探讨表皮生长因子受体家族EGFR、c-erbB-2和c-erbB-3三种蛋白的共同表达与大肠良恶性肿瘤的关系。方法:选取病理检查证实的大肠息肉、大肠腺瘤和大肠腺癌共151例,采用免疫组化ENVISION技术分别对所选取的标本进行EGFR、c-erbB-2和c-erbB-3检测,并对结果进行统计学分析。结果:增生性息肉组EGFR、c-erbB-2和c-erbB-3三者单一表达或三者均不表达的比率较高(42.86％和35.71％),二者和三者共同表达的比率低(19.05％和2.38％);腺瘤与腺癌组均出现较高的二者和三者同时表达的比率,而三者共同表达在腺癌组中的比率明显高于息肉组和腺瘤组(P<0.01)。大肠息肉中,c-erbB-2单一表达率较高(28.57％) ;腺瘤和腺癌中分别有一种蛋白不出现单一表达,为c-erbB-3和c-erbB-2;在大肠息肉和腺瘤中,均未出现有c-erbB-3与EGFR的共同表达。结论:在不同类型的大肠肿瘤中,EGFR家族蛋白的表达或共同表达具有不同特点;在大肠癌的发生发展中,三种蛋白在信号传导过程中呈共同表达。     

吉非替尼对表皮生长因子受体在胆管上皮细胞中表达的影响及意义

目的通过观察吉非替尼对肝内病变胆管上皮细胞中表皮生长因子受体(EGFR)表达的影响,探讨抑制胆管上皮细胞过度增殖的可行性。方法选择双流县第一人民医院2006年8月至2008年8月期间住院需要手术的肝内胆管结石患者共61例,年龄25～65岁(平均46.92岁),随机分为治疗组和对照组。治疗组30例,术中在病变胆管内留置细导管,术后灌注吉非替尼溶液;对照组31例只作T管引流。分别于术中、术后6周和12周行胆道镜碎石及取石的同时,活检灌注处的病变胆管壁组织,行HE染色、免疫组化和RT-PCR检测,观察组织学变化和EGFR的表达。结果术中,2组胆管壁病理组织学改变及EGFR蛋白和mRNA表达无明显差异。术后6周和12周,治疗组的胆管黏膜上皮和黏膜下腺体增殖程度均较对照组明显减弱,EGFR蛋白表达较对照组明显减弱,EGFR mRNA表达明显低于对照组(P0.05)。结论 EGFR在慢性增生性胆管炎中呈过表达状态,术后局部持续给予吉非替尼治疗能够特异性地阻断EGFR的激活和表达,能有效地抑制术后胆管上皮细胞的过度增殖。     

Relationships between Ki-67 labelling index,amplification of the epidermal growth factor receptor gene,and prognosis in human glioblastomas

Summary The aim of this study was to determine possible relationships between Ki-67 labelling index (Ki-67 LI), amplification of the epidermal growth factor receptor (EGFR) gene, and prognosis in human glioblastomas. Ki-67 LI was determined on cryosections of biopsy specimens of 20 human glioblastomas with a mouse antihuman Ki-67 monoclonal antibody. Amplification of the EGFR gene was determined by slot blot and Southern blot analyses of DNA extracted from the tumour biopsies. The Ki-67 LI was higher in the glioblastoma group with EGFR gene amplification (8 tumours, median value of Ki-67 LI 4.2, range 0.4–24.6) than in those without EGFR gene amplification (12 tumours, median value of Ki-67 LI 0.8, range 0.2–11.8) (0.05 p<0.1). The glioblastoma patients with Ki-67 LI>1.5 (10 tumours) had a statistically significant shorter survival than those with Ki-67 LI<1.5 (10 tumours) (p<0.05). The glioblastoma patients with EGFR gene amplification lived shorter time than those without EGFR gene amplification (p>0.05).     

Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients

BACKGROUND: Unlike other human tumors, gastric cancer remains a great therapeutic challenge since no standardized postoperative treatment exists. Knowledge of molecular pathways determining the behavior of individual gastric tumors seems to be crucial for therapeutic decisions, and evaluation of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression might be critical for prognosis, assessment, and identification of patients that could be treated with tailored therapies. METHODS: VEGF and EGFR determination was performed in 88 gastric cancer samples as well as 25 normal gastric mucosa specimens from non-cancer patients using a commercially available immunohistochemistry kit. In all samples, the correlation of VEGF and EGFR expression was investigated with each other, and with other prognostic indicators in all samples, and, finally, with survival rates in 69 patients undergoing potentially curative surgery. RESULTS: Forty-eight per cent (42 cases) of gastric cancers expressed VEGF, and 44% (39 cases) stained for EGFR. In curatively treated patients, VEGF and EGFR expression was demonstrated to correlate with worse survival in both univariate and multivariate analyses. Molecular profiling was shown to more accurately estimate the risk of cancer-related death than TNM stage, and, of most interest, to allow sorting out high-risk patients within the same stage. CONCLUSIONS: These findings provide evidence that contemporary evaluation of VEGF and EGFR expression may be crucial to select gastric cancer patients with poor prognosis who may benefit of tailored treatments.     

少突胶质细胞肿瘤1p/19q联合缺失与p53、10号染色体上磷酸酶及张力蛋白同源物和6-甲基鸟嘌呤-DNA甲基转移酶蛋白表达的关系

目的 探讨少突胶质细胞肿瘤染色体1p/19q联合缺失及其与p53、10号染色体上磷酸酶及张力蛋白同源物( PTEN)和O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)蛋白表达的关系.方法 收集少突胶质细胞肿瘤标本68例,其中WHO-Ⅱ级少突胶质细胞瘤42例,WHO-Ⅲ级间变性少突胶质细胞瘤26例.采用荧光原位杂交(FISH)方法分析肿瘤组织中1p/19q缺失状态；采用免疫组织化学方法对肿瘤组织中p53、PTEN和MGMT蛋白表达进行半定量分析,并进一步分析其与1p/19q联合缺失的相关性.结果 68例少突胶质细胞肿瘤中,染色体1 p、19q缺失率及1p/19q联合缺失率分别为67.65％ (46/68)、61.76％( 42/68)、57.35％(39/68).1p/19q联合缺失率在Ⅱ级和Ⅲ级少突胶质细胞肿瘤之间,差异无统计学意义(P＞0.05).1p/19q联合缺失在额叶肿瘤的发生率(76.67％,23/30)明显高于颞叶(45.00％,9/20)及其他部位肿瘤(38.89％,7/18),差异有统计学意义(P＜0.05).tp/19q联合缺失与患者性别及发病年龄无明显相关(P＞0.05).p53和MGMT蛋白表达与肿瘤分级呈正相关,而PTEN表达与肿瘤分级呈负相关,差异均有统计学意义(P＜0.05).1p/19q联合缺失与p53和MGMT蛋白低表达相关(P＜0.05),而与PTEN蛋白表达无明显相关(P＞0.05).结论 在少突胶质细胞肿瘤中,染色体1p/19q联合缺失与p53和MGMT蛋白表达水平呈负相关.